ArticleThe oncologist2020
The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas.
Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Primary neuroendocrine tumors of the breast according to the WHO 2019 classification; real life experiences of rare tumor types of the breast.The oncologist · 2025Article
- Neuroendocrine Breast Cancer-Associated Ectopic Adrenocorticotropic Hormone Syndrome Requiring Bilateral Adrenalectomy.Current oncology (Toronto, Ont.) · 2025Article
- Primary Neuroendocrine Carcinoma of Breast: Changing Paradigm.Indian journal of surgical oncology · 2025Article
- Neuroendocrine Neoplasms of the Breast: Current Insights and Future Directions.Cancer reports (Hoboken, N.J.) · 2024Review
- The Association of Neuroendocrine Differentiation with MicroRNA 21 and MicroRNA let7f Expression and the Clinicopathological Parameters in Primary Invasive Breast Carcinomas with Neuroendocrine Features.Diagnostics (Basel, Switzerland) · 2024Article
- Neuroendocrine neoplasms of the breast: a review of literature.Virchows Archiv : an international journal of pathology · 2024Review
- Neuroendocrine Breast Carcinoma: Interesting Images of an Underdiagnosed Entity.Diagnostics (Basel, Switzerland) · 2024Article
- [Neuroendocrine expression markers in triple-negative, luminal-A, luminal-B and HER2neu breast cancer].Revista medica del Instituto Mexicano del Seguro Social · 2024Observational
- Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).The journal of pathology. Clinical research · 2023Article
- Metaplastic breast carcinoma producing prominent basal lamina with neuroendocrine differentiation: A case report.Molecular and clinical oncology · 2023Article
- Differences in clinical characteristics and prognosis between breast neuroendocrine carcinoma and breast invasive ductal carcinoma: A multicentre population-based study from China.Cancer medicine · 2023Article
- Primary neuroendocrine breast cancer-an unusual occurrence.Ecancermedicalscience · 2023Article
- Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3.Human pathology · 2022Article
- The classification of neuroendocrine neoplasms of the breast and its clinical relevance.Virchows Archiv : an international journal of pathology · 2022Review
- Prognostic factors of primary neuroendocrine breast cancer: A population-based study.Cancer medicine · 2022Article
- Clinical and genomic analyses of neuroendocrine neoplasms of the breast.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives.Frontiers in oncology · 2022Review
- Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature.Cancers · 2021Review
- Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Review
- Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues.Frontiers in endocrinology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The latest World Health Organization (WHO) classification categorized invasive breast carcinomas (IBCs) with neuroendocrine (NE) differentiations into neuroendocrine neoplasms (including well-differentiated neuroendocrine tumor [NET] and poorly differentiated neuroendocrine carcinoma [NEC]) and IBC no special type with NE features (IBC-NST-NE). However, little is documented of the clinical significance of this classification; also the precise thresholds and choices of NE markers were variable. In the current study, a large cohort of patients with IBC with NE differentiation were morphologically classified based on the WHO criteria and the clinical relevance of expression of different NE markers (synaptophysin [SYN], chromogranin [CG], and CD56) was evaluated. Among 1,372 IBCs, 52 NET (3.8%) and 172 IBC-NST-NE (12.5%) were identified. Compared with the IBC-no NE cases, NET and IBC-NST-NE were similarly associated with positive estrogen receptor (ER) expression and lower grade (p < .001). For patient outcome, IBC-NST-NE, but not NET, demonstrated significantly worse survival than the IBC-no NE cases. Based on high (≥50%) and low (<50%) expression for each NE marker, independent poor disease-free survival for SYN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.